Zogenix, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2006-01-01
- Employees
- 327
- Market Cap
- -
- Website
- http://n/a
Clinical Trials
19
Trial Phases
4 Phases
Drug Approvals
3
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder
- Conditions
- CDKL5 Deficiency DisorderGeneralized Tonic Clonic SeizureEpileptic SpasmRefractory Seizures
- Interventions
- Drug: ZX008 (Fenfluramine Hydrochloride)Drug: Matching ZX008 Placebo
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Zogenix, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT05064878
- Locations
- 🇺🇸
Ep0216 154, Birmingham, Alabama, United States
🇺🇸Ep0216 144, Los Angeles, California, United States
🇺🇸Ep0216 101, San Francisco, California, United States
European Non-interventional Study on Refractory Epilepsy With Developmental Delay
- Conditions
- Refractory EpilepsyDevelopment Delay
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Zogenix, Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT04398667
- Locations
- 🇫🇷
Unité de neuropédiatrie, CHU Angers, Angers, France
🇫🇷Department of Neurology - Foundation John Bost, La Force, France
🇫🇷Hospital St Louis DRCI, CHU Bicêtre, Paris, France
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
- Conditions
- Dravet SyndromeLennox Gastaut SyndromeEpileptic Encephalopathy
- Interventions
- Drug: ZX008 (Fenfluramine Hydrochloride)
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Zogenix, Inc.
- Target Recruit Count
- 412
- Registration Number
- NCT03936777
- Locations
- 🇺🇸
Ep0215 107, Tucson, Arizona, United States
🇺🇸Ep0215 144, Los Angeles, California, United States
🇺🇸Ep0215 108, San Diego, California, United States
ZX008 Expanded Access Protocol
- Conditions
- Dravet Syndrome
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Zogenix, Inc.
- Registration Number
- NCT03780127
Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia
- Conditions
- Schizoaffective DisorderSchizophrenia
- Interventions
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Zogenix, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02411526
- Locations
- 🇺🇸
Collaborative Neuroscience Network, Long Beach, California, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
Needle-Free Drug Delivery Devices Market Set to Reach $5+ Billion by 2035
The needle-free injection system market is projected to grow at a CAGR of 4% from $606 million in 2024 to 2035, driven by increasing chronic disease prevalence and patient preference for painless administration.